# Johnson & Johnson to Acquire Halda Therapeutics for $3.05Billion
November 18, 2025 (Global) – Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics, a clinical‑stage biotechnology company, in an all‑cash deal valued at approximately $3.05billion. The acquisition aims to strengthen J&J’s oncology pipeline, particularly in targeted therapies for solid tumors, including prostate cancer. (pharmaceutical-technology.com)
“This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid‑ and long‑term catalyst for growth,” said Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine at Johnson & Johnson.
Halda Therapeutics is recognized for its proprietary Regulated Induced Proximity Targeting Chimera (RIPTAC) platform, designed to selectively target and kill cancer cells. Its lead clinical candidate, HLD‑0915, is an oral therapy currently in Phase1/2 development for metastatic castration‑resistant prostate cancer, showing promising preliminary results. The acquisition also includes several early-stage RIPTAC programs for other solid tumors such as breast and lung cancers.
The deal aligns with Johnson & Johnson’s strategy to expand its oncology offerings and accelerate the development of innovative therapies. By combining Halda’s pipeline with J&J’s global R&D, manufacturing, and commercial capabilities, the company aims to bring new treatment options to patients more efficiently.
Key Highlights of the Acquisition
- Acquisition valued at $3.05billion in cash
- Strengthens J&J’s oncology pipeline with focus on solid tumors and prostate cancer
- Includes Halda’s RIPTAC platform and lead candidate HLD‑0915
- Expected to close within the coming months, pending regulatory approvals
- Aims to accelerate clinical development and expand patient access
This acquisition underscores Johnson & Johnson’s commitment to advancing targeted cancer therapies and reinforces its position in a competitive and rapidly evolving oncology landscape.
